Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway it actually can make with these reforms.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Short interest in Pfizer Inc. (NYSE: PFE) decreased to 47.57 million shares from the previous 65.04 million. The stock was trading at $40.64 Friday morning, within a 52-week range of $34.89 to $46.47.
The number of Merck & Co. Inc. (NYSE: MRK) shares short fell to 14.32 million from 22.31 million in the previous period. Its shares were trading at $78.33, in a 52-week range of $57.49 to $83.85.
Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest increase to 91.49 million shares from the previous reading of 77.46 million. Shares traded at $47.23, in a 52-week trading range of $44.30 to $63.69.
The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 21.82 million from the previous 27.58 million. The stock was trading at $77.91, and its 52-week range is $75.77 to $107.25.
Eli Lilly and Co.’s (NYSE: LLY) short interest shrank to 16.66 million shares from the previous 26.97 million. The stock was trading at $115.80. The 52-week range is $79.41 to $132.13.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest fell to 17.84 million from the previous level of 18.18 million. Shares were trading at $14.47, in a 52-week range of $14.04 to $25.96.
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
